Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1090P is a processed pseudogene belonging to the U6 small nuclear RNA (snRNA) family. U6 snRNAs are essential components of the spliceosome that catalyze pre-mRNA splicing, but the pseudogene form (such as RNU6-1090P) does not encode a functional RNA or protein. Pseudogenes are typically non-functional copies of coding or non-coding genes and often result from retrotransposition or duplication events. While most pseudogenes are transcriptionally silent, some are transcribed and may regulate the expression of related genes by acting as decoys for regulatory molecules (e.g., miRNAs) or forming double-stranded RNAs that participate in RNA interference pathways[4][6][5]. There is no evidence that RNU6-1090P is involved in a specific biological process, is a therapeutic target, or is associated with disease. It is not a receptor, enzyme, or druggable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1090, pseudogene (RNU6-1090P).